Expertise in
1
conditions

Martine Gardembas

Angers, FR 
Expertise in
1
conditions
Angers, FR 

Overview

Martine Gardembas practices practicing medicine in Angers, France.

Ms. Gardembas is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Leukemia, Primary Immunodeficiency (PID), and Agranulocytosis.

She is actively involved in clinical research, co-authoring 32 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Angers, France
Other Locations
CHU de Pontchaillou
Rennes, France
CHU Côte de Nacre
Caen, 14000, France
Lyon, France
CHU Brabois Vandoeuvre
Nancy, France
France
Bordeaux, France
Rue Michel Polonovski, Lille, 59037, France
Toulouse, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission
A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission
Enrollment Status: Completed
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drugs: Ponatinib, Cytarabine
Study Phase: Phase 1/Phase 2
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Enrollment Status: Completed
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
View 2 Less Clinical Trials

32 Total Publications

Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Journal: The Journal of allergy and clinical immunology
Published: April 08, 2023

Frequently Asked Questions about Martine Gardembas

Is Martine Gardembas a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Martine Gardembas is classified as an Advanced expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Martine Gardembas participate in research or clinical trials?

Yes. Martine Gardembas has published 32 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Martine Gardembas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gardembas's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile